Food Allergy News and Research

Kids With Food Allergies will recap some of the top research in food allergies every three months. Here is a look at studies reported between January and March. Read about teens and food allergy, peanut allergy, secondhand smoke and more.

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, announced clinical data presented today at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Atlanta. The presentations included Phase 3 screening data and Phase 2 adherence data from Aimmune’s AR101 program. AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy.

Secondhand smoke exposure is a well-established risk factor for asthma, but it may also have surprising effects in the development of diseases outside of the respiratory system. In the first study of its kind, researchers in Sweden investigated the link between early life secondhand smoke exposure and pediatric food-related symptoms.

After the success of the yearlong double-blind, placebo controlled randomized Phase IIb trial for a peanut patch, known as Viaskin® Peanut, researchers continued the trial two more years in an open label extension to ascertain the effect of long-term treatment.

The American Academy of Pediatrics (AAP) reaffirmed epinephrine as the first choice to treat severe allergic reactions. And to make certain parents, caregivers and others are ready to treat anaphylaxis, the AAP released its own version of a food allergy action plan . 1 Download PDF The recommendations were released in the February 13 edition of the journal Pediatrics . 2 The report stresses that it is better to use epinephrine early, even if parents are not 100% sure that the symptoms are...

If you live in New Jersey, take action now by urging your local representative in the New Jersey state legislature to move a bill through the legislative process that covers the cost of special formula for eosinophilic disorders regardless of delivery method. The bill, S2649, gives health insurance coverage for amino acid-based elemental formulas (like Neocate® or EleCare®) for eosinophilic disorders. The bill provides coverage for elemental formula no matter how it is delivered. An infant...

People at risk for anaphylaxis can begin ordering AUVI-Q® epinephrine auto-injectors today through Kaléo’s direct delivery service. According to the company, it is also launching its AUVI-Q Afford Ability ™ program: People with commercial insurance will have an out-of-pocket cost of $0 - even if their insurance company will not cover AUVI-Q. That also applies to those with high-deductible plans. For patients who do not have government or commercial insurance, and have a household income of...

Does your family have food allergies? If so, we invite you to inform food allergy research. Our Food Allergy Patient & Family Registry (Registry) is a web-based program that gives you a place to share your experiences. The Registry is a program to collect, manage and analyze data from and about people with food allergies. It will advance research through patient information. Our goal is to find ways to prevent and cure food allergy. The first and only “patient-centered” food allergy...

The new guidelines recommend introduction of peanut-containing foods to infants as early as 4 and 6 months of age. How peanut-containing foods should be introduced to infants depends on the infant’s risk level.

Epinephrine is a lifesaving medicine for people with severe allergies. It’s awful to think that some Americans have to choose between putting food on the table and putting an epinephrine auto-injector in their child’s backpack. It is important to discuss with your physician about what is the most appropriate prescription for your family. You may also need to find out which options your insurance provider prefers. This will affect your out-of-pocket costs. Each device has its own unique set...

Kaléo announces AUVI-Q returning to market 2/14 with pricing aimed at making its auto-injector affordable.

New guidelines released in 2017 may help prevent the development of peanut allergy. The guidelines recommend early introduction of peanut-containing foods to infants as early as 4 and 6 months of age. How peanut-containing foods should be introduced to infants depends on the infant’s risk level. Join us for a free webinar on January 26, 2017 at 3 pm EST.